Exciting News Out of Stockholm for ER+ Resistant Cancer

Adding the drug everolimus to the aromatase inhibitor exemestane "more than doubled the time women lived without tumor growth and cut risk of their disease worsening by 57% versus hormonal therapy alone." See:
Novartis Drug Helps Women With Advanced Breast Cancer

This from the source below:

"Coupling everolimus with exemestane (an aromatase inhibitor) has produced such dramatic disease control in women with advanced hormone resistant, estrogen receptor-positive breast cancer that it is expected to transform the management of these patients."

Everolimus Posts Big Win in ER-Postive Breast Cancer

http://www.oncologystat.com/news/Everolimus_Posts_Big_Win_in_ER-Positive_Breast_Cancer__US.html